Vimseltinib

Overview

Vimseltinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL5095202).

Patent & exclusivity (US)

Per the FDA Orange Book (3 approved US products), the latest listed US patent on Vimseltinib expires 30 Apr 2045 and exclusivity 14 Feb 2030. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

3-methyl-5-[6-methyl-5-[[2-(1-methylpyrazol-4-yl)-4-pyridinyl]oxy]-2-pyridinyl]-2-(propan-2-ylamino)pyrimidin-4-one

Canonical SMILES

CC1=C(C=CC(=N1)C2=CN=C(N(C2=O)C)NC(C)C)OC3=CC(=NC=C3)C4=CN(N=C4)C

InChIKey

TVGAHWWPABTBCX-UHFFFAOYSA-N